ADAM17 and COVID-19: This so-called trans-signaling pathway is thought to mainly account for the pro-inflammatory properties of IL-6, and it would be exacerbated under conditions of increased both ADAM17 expression and circulating IL-6 levels, as observed in the present study in COVID-19 patients depending on the disease severity outcome.